Clinical characteristics of leiomyosarcoma of bone and soft tissue of extracted cases with or without adjuvant chemotherapy
| Characteristics . | Bone (N = 33) . | Soft tissue (N = 539) . | ||||
|---|---|---|---|---|---|---|
| . | Adjuvant chemotherapy . | Adjuvant chemotherapy . | ||||
| . | + (N = 20) . | − (N = 13) . | P value . | + (N = 118) . | − (N = 421) . | P value . |
| Sex | 0.51 | 0.42 | ||||
| Male | 10 (50%) | 8 (61.5%) | 68 (57.6%) | 225 (53.4%) | ||
| Female | 10 (50%) | 5 (38.5%) | 50 (42.4%) | 196 (46.6%) | ||
| Age (years), median | 41 (range 21-76) | 62 (range 18-80) | 0.07 | 59 (range 29-81) | 70 (range 13-96) | <0.0001 |
| Primary location | 0.13 | 0.22 | ||||
| Upper extremity | 0 (0%) | 2 (15.4%) | 12 (10.2%) | 69 (16.4%) | ||
| Lower extremity | 15 (75%) | 9 (69.2%) | 76 (64.4%) | 248 (58.9%) | ||
| Trunk | 5 (25%) | 2 (15.4%) | 30 (25.4%) | 104 (24.7%) | ||
| Tumor size(cm), median | 7.3 (range 4-23) | 6 (range 3-10) | 0.06 | 8 (range 1.3-29.2) | 5.6 (range 0.5-22) | <0.0001 |
| <8 | 12 (60%) | 11 (84.6%) | 0.12 | |||
| ≥8 | 8 (40%) | 2 (15.4%) | ||||
| <5 | 19 (17.3%) | 148 (38.5%) | <0.0001 | |||
| ≥5, <10 | 48 (43.6%) | 147 (38.3%) | ||||
| ≥10 | 43 (39.1%) | 89 (23.2%) | ||||
| Adjuvant raidotherapy | 0 | 0 | 17 (14.4%) | 50 (11.9%) | 0.47 | |
| Surgical margin | 0.68 | 0.46 | ||||
| R1 or R2 | 4 (21.1%) | 2 (15.4%) | 8 (6.8%) | 37 (9%) | ||
| R0 | 15 (78.9%) | 11 (84.6%) | 109 (93.2%) | 376 (91%) | ||
| Characteristics . | Bone (N = 33) . | Soft tissue (N = 539) . | ||||
|---|---|---|---|---|---|---|
| . | Adjuvant chemotherapy . | Adjuvant chemotherapy . | ||||
| . | + (N = 20) . | − (N = 13) . | P value . | + (N = 118) . | − (N = 421) . | P value . |
| Sex | 0.51 | 0.42 | ||||
| Male | 10 (50%) | 8 (61.5%) | 68 (57.6%) | 225 (53.4%) | ||
| Female | 10 (50%) | 5 (38.5%) | 50 (42.4%) | 196 (46.6%) | ||
| Age (years), median | 41 (range 21-76) | 62 (range 18-80) | 0.07 | 59 (range 29-81) | 70 (range 13-96) | <0.0001 |
| Primary location | 0.13 | 0.22 | ||||
| Upper extremity | 0 (0%) | 2 (15.4%) | 12 (10.2%) | 69 (16.4%) | ||
| Lower extremity | 15 (75%) | 9 (69.2%) | 76 (64.4%) | 248 (58.9%) | ||
| Trunk | 5 (25%) | 2 (15.4%) | 30 (25.4%) | 104 (24.7%) | ||
| Tumor size(cm), median | 7.3 (range 4-23) | 6 (range 3-10) | 0.06 | 8 (range 1.3-29.2) | 5.6 (range 0.5-22) | <0.0001 |
| <8 | 12 (60%) | 11 (84.6%) | 0.12 | |||
| ≥8 | 8 (40%) | 2 (15.4%) | ||||
| <5 | 19 (17.3%) | 148 (38.5%) | <0.0001 | |||
| ≥5, <10 | 48 (43.6%) | 147 (38.3%) | ||||
| ≥10 | 43 (39.1%) | 89 (23.2%) | ||||
| Adjuvant raidotherapy | 0 | 0 | 17 (14.4%) | 50 (11.9%) | 0.47 | |
| Surgical margin | 0.68 | 0.46 | ||||
| R1 or R2 | 4 (21.1%) | 2 (15.4%) | 8 (6.8%) | 37 (9%) | ||
| R0 | 15 (78.9%) | 11 (84.6%) | 109 (93.2%) | 376 (91%) | ||
Clinical characteristics of leiomyosarcoma of bone and soft tissue of extracted cases with or without adjuvant chemotherapy
| Characteristics . | Bone (N = 33) . | Soft tissue (N = 539) . | ||||
|---|---|---|---|---|---|---|
| . | Adjuvant chemotherapy . | Adjuvant chemotherapy . | ||||
| . | + (N = 20) . | − (N = 13) . | P value . | + (N = 118) . | − (N = 421) . | P value . |
| Sex | 0.51 | 0.42 | ||||
| Male | 10 (50%) | 8 (61.5%) | 68 (57.6%) | 225 (53.4%) | ||
| Female | 10 (50%) | 5 (38.5%) | 50 (42.4%) | 196 (46.6%) | ||
| Age (years), median | 41 (range 21-76) | 62 (range 18-80) | 0.07 | 59 (range 29-81) | 70 (range 13-96) | <0.0001 |
| Primary location | 0.13 | 0.22 | ||||
| Upper extremity | 0 (0%) | 2 (15.4%) | 12 (10.2%) | 69 (16.4%) | ||
| Lower extremity | 15 (75%) | 9 (69.2%) | 76 (64.4%) | 248 (58.9%) | ||
| Trunk | 5 (25%) | 2 (15.4%) | 30 (25.4%) | 104 (24.7%) | ||
| Tumor size(cm), median | 7.3 (range 4-23) | 6 (range 3-10) | 0.06 | 8 (range 1.3-29.2) | 5.6 (range 0.5-22) | <0.0001 |
| <8 | 12 (60%) | 11 (84.6%) | 0.12 | |||
| ≥8 | 8 (40%) | 2 (15.4%) | ||||
| <5 | 19 (17.3%) | 148 (38.5%) | <0.0001 | |||
| ≥5, <10 | 48 (43.6%) | 147 (38.3%) | ||||
| ≥10 | 43 (39.1%) | 89 (23.2%) | ||||
| Adjuvant raidotherapy | 0 | 0 | 17 (14.4%) | 50 (11.9%) | 0.47 | |
| Surgical margin | 0.68 | 0.46 | ||||
| R1 or R2 | 4 (21.1%) | 2 (15.4%) | 8 (6.8%) | 37 (9%) | ||
| R0 | 15 (78.9%) | 11 (84.6%) | 109 (93.2%) | 376 (91%) | ||
| Characteristics . | Bone (N = 33) . | Soft tissue (N = 539) . | ||||
|---|---|---|---|---|---|---|
| . | Adjuvant chemotherapy . | Adjuvant chemotherapy . | ||||
| . | + (N = 20) . | − (N = 13) . | P value . | + (N = 118) . | − (N = 421) . | P value . |
| Sex | 0.51 | 0.42 | ||||
| Male | 10 (50%) | 8 (61.5%) | 68 (57.6%) | 225 (53.4%) | ||
| Female | 10 (50%) | 5 (38.5%) | 50 (42.4%) | 196 (46.6%) | ||
| Age (years), median | 41 (range 21-76) | 62 (range 18-80) | 0.07 | 59 (range 29-81) | 70 (range 13-96) | <0.0001 |
| Primary location | 0.13 | 0.22 | ||||
| Upper extremity | 0 (0%) | 2 (15.4%) | 12 (10.2%) | 69 (16.4%) | ||
| Lower extremity | 15 (75%) | 9 (69.2%) | 76 (64.4%) | 248 (58.9%) | ||
| Trunk | 5 (25%) | 2 (15.4%) | 30 (25.4%) | 104 (24.7%) | ||
| Tumor size(cm), median | 7.3 (range 4-23) | 6 (range 3-10) | 0.06 | 8 (range 1.3-29.2) | 5.6 (range 0.5-22) | <0.0001 |
| <8 | 12 (60%) | 11 (84.6%) | 0.12 | |||
| ≥8 | 8 (40%) | 2 (15.4%) | ||||
| <5 | 19 (17.3%) | 148 (38.5%) | <0.0001 | |||
| ≥5, <10 | 48 (43.6%) | 147 (38.3%) | ||||
| ≥10 | 43 (39.1%) | 89 (23.2%) | ||||
| Adjuvant raidotherapy | 0 | 0 | 17 (14.4%) | 50 (11.9%) | 0.47 | |
| Surgical margin | 0.68 | 0.46 | ||||
| R1 or R2 | 4 (21.1%) | 2 (15.4%) | 8 (6.8%) | 37 (9%) | ||
| R0 | 15 (78.9%) | 11 (84.6%) | 109 (93.2%) | 376 (91%) | ||
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
